Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) plus linagliptin (lina) vs ramucirumab (ram) plus paclitaxel (pac) in MORPHEUS-gastric cancer

被引：0
|
作者：
Lee, J. [1 ]
Ajani, J. A. [2 ]
Chung, H. C. [3 ]
Kang, Y-K. [4 ]
Iqbal, S. [5 ]
Allen, S. [6 ]
Al-Sakaff, N. [7 ]
Decalf, J. [8 ]
Li, S. [9 ]
Pintoffl, J. [7 ]
Sayyed, P. [7 ]
Bang, Y-J. [10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Oncol, Seoul, South Korea
[2] MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] USC Norris Comprehens Canc Ctr, Dept Oncol, Los Angeles, CA USA
[6] Genentech Inc, Oncol Biomarker Dev, South San Francisco, CA USA
[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
[8] Genentech Inc, Dept Canc Immunol, South San Francisco, CA USA
[9] Biostat Roche China Holding Ltd, Shanghai, Peoples R China
[10] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1382P
引用
收藏
页码：S1047 / S1047
页数：1
相关论文
共 50 条
  • [21] Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial.
    Taieb, Julien
    Borg, Christophe
    Lecomte, Thierry
    Lepere, Celine
    Chatellier, Thierry
    Smith, Denis Michel
    Dubreuil, Patrice
    Mansfield, Colin
    Moussy, Alain
    Hermine, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
    Rha, Sun Young
    Kim, Chang Gon
    Jung, Minkyu
    Kim, Hyo Song
    Lee, Choong-kun
    Jeung, Hei-Cheul
    Koo, Dong-Hoe
    Bae, Woo Kyun
    Zang, Dae Young
    Kim, Hyunki
    Chung, Hyun Cheol Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
    Drakaki, Alexandra
    Powles, Thomas
    Bamias, Aristotelis
    Martin-Liberal, Juan
    Shin, Sang Joon
    Friedlander, Terence
    Tosi, Diego
    Park, Chandler
    Gomez-Roca, Carlos
    Lobbedez, Florence Joly
    Castellano, Daniel
    Morales-Barrera, Rafael
    Moreno-Candilejo, Irene
    Flechon, Aude
    Yuen, Kobe
    Rishipathak, Deepali
    Dupree, Kelly
    Young, Fiona
    Michielin, Francesca
    Shemesh, Colby S.
    Steinberg, Elizabeth E.
    Williams, Patrick
    Lee, Jae Lyun
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4373 - 4384
  • [24] Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Sawada, Kentaro
    Nakamura, Michio
    Muto, Osamu
    Sogabe, Susumu
    Shindo, Yoshiaki
    Ishiguro, Atsushi
    Sato, Atsushi
    Tsuji, Yasushi
    Dazai, Masayoshi
    Okuda, Hiroyuki
    Meguro, Takashi
    Harada, Kazuaki
    Sekiguchi, Mari
    Okada, Kazufumi
    Ito, Yoichi M.
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    ONCOLOGIST, 2022, 27 (08): : E642 - E649
  • [25] Neoadjuvant capecitabine plus paclitaxel in gastric cancer patients with liver metastasis: an open-label, uncontrolled, prospective phase II clinical study
    Yuan, P.
    Wu, A.
    Li, Z.
    Tang, L.
    Bu, Z.
    Ren, H.
    Ji, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 63 - 63
  • [26] Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.
    Wang, Fenghua
    Ren, Chao
    Xu, Jianying
    Wang, Zhiqiang
    He, Ming-ming
    Qiu, Miaozhen
    Jin, Ying
    Luo, Huiyan
    Wang, Feng
    Li, Yuhong
    Tan, Qiong
    Zhang, Rong
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
    Lorenzen, Sylvie
    Thuss-Patience, Peter
    Pauligk, Claudia
    Goekkurt, Eray
    Ettrich, Thomas
    Lordick, Florian
    Stahl, Michael
    Reichardt, Peter
    Soekler, Martin
    Pink, Daniel
    Probst, Stefan
    Hinke, Axel
    Goetze, Thorsten O.
    Al-Batran, Salah E.
    EUROPEAN JOURNAL OF CANCER, 2022, 165 : 48 - 57
  • [28] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [29] Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study
    Wu, Ai-Wen
    Yuan, Peng
    Li, Zi-Yu
    Tang, Lei
    Bu, Zhao-De
    Ren, Hui
    Ji, Jia-Fu
    FUTURE ONCOLOGY, 2016, 12 (18) : 2107 - 2116
  • [30] Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial
    Li, Jin
    Huang, Mingzhu
    Deng, Ting
    Bai, Yuxian
    Liu, Tianshu
    Pan, Yueyin
    Yu, Junyan
    Pan, Hongming
    Xu, Huiting
    Wang, Jufeng
    Ye, Feng
    Wang, Junye
    Wu, Jinsheng
    Cang, Shundong
    Chen, Kehe
    Zhang, Jun
    Zhang, Jingdong
    Ling, Yang
    Liu, Yin
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345